No Data
Zhejiang Orient Gene Biotech's Unit Gets Certificate to Conduct Research in US
Zhejiang Orient Gene Biotech (688298.SH): accumulated repurchased 8.3327 million shares of the company's stock.
On September 2, Gelon Hui announced that as of August 31, 2024, Zhejiang Orient Gene Biotech (688298.SH) had repurchased a total of 8.3327 million shares of the company through the Shanghai Stock Exchange system through centralized competitive bidding, accounting for 4.13% of the total share capital of 201.6 million shares. The lowest price for repurchase transactions was 27.83 yuan per share, the highest price was 34.50 yuan per share, and the total amount paid for the repurchase was 0.275 billion yuan.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Zhejiang Orient Gene Biotech (688298.SH): Net loss of 0.152 billion yuan in the first half of the year.
Zhejiang orient gene biotech (688298.SH) released its semi-annual report for 2024, with revenue of 0.418 billion yuan in the first half of the year, a year-on-year decrease of 16.61%; net income attributed to shareholders of listed companies was -0.152 billion yuan.
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?No Data
